bradley mcgregor, md, considers strategies for treating 2nd line rcc patients
Published 5 years ago • 28 plays • Length 1:18
Download video MP4
Download video MP3
Similar videos
-
2:09
bradley mcgregor, md, considers the optimal approach to treating newly diagnosed rcc patients
-
1:01
bradley mcgregor, md, describes if biomarkers help guide treatment in advanced renal cell carcinoma
-
1:13
bradley mcgregor, md, on mrcc patients whose cancer returns and were previously treated with i-o
-
1:19
bradley mcgregor, md, on impressions of the oral inhibitor study in renal cell carcinoma patients
-
1:49
bradley mcgregor, md, discusses checkmate-214 investigating nivolumab ipilimumab in rcc patients
-
1:29
bradley mcgregor, md, on combo ipilimumab nivolumab in variant histologies of bladder cancer
-
0:53
dr. mcgregor on challenges facing frontline treatments for rcc
-
9:57
how to select 1st line therapy for metastatic renal cell cancer?
-
8:50
comparison of frontline renal cell carcinoma treatment options
-
32:03
the future of vaccine treatment in brain cancer by robert prins, md
-
2:31
toni choueiri, md, describes treatment strategies for 2nd line renal cell carcinoma
-
2:06
dr. mcgregor on whether patients need frontline combinations in rcc
-
1:16
bradley mcgregor, md, on the data regarding enfortumab in post-platinum i-o bladder cancer
-
0:56
dr mcgregor on the future implications of ongoing research in rcc
-
1:03
dr. mcgregor on the evolving treatment landscape of rcc
-
1:49
dr. mcgregor on immunotherapy combinations in kidney cancer
-
1:08
dr. mcgregor on unmet needs in non-clear cell rcc
-
1:47
dr. mcgregor on choosing a combination therapy regimen in advanced rcc
-
2:10
esmo23: brad mcgregor, md | dana-farber cancer institute
-
1:32
bradley mcgregor, md, shares presented data investigating atezolizumab and cabozantinib in mcrpc
-
22:31
kidney cancer conference highlights from asco 2022
-
1:02
current status of vegf inhibitor/immunotherapy combinations in rcc
Clip.africa.com - Privacy-policy